A Second-Look TUR in T1 Transitional Cell Carcinoma: Why?

Jakse, G.; Algaba, Ferrán; Malmström, Per‐Uno; Oosterlinck, Willem

doi:10.1016/j.eururo.2003.12.016

Cited by 182 publications

(90 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients who had a history of a previous TUR, high-grade tumor and intravesical therapy were excluded from the study in order to establish a homogeneous group of patients and to avoid the effect of intravesical treatment on recurrence. In univariate and multivariate analyses, in accordance with the literature, the presence of tumor multiplicity and MP presence were determined as the factors predicting recurrence (6,11,12,15,20,21). Recurrence has been shown to be statistically significantly more frequent in patients with non-MP ( Table 2).…”

Section: Mariappan Et Al (6) Have Demonstrated That (I) Multiplicitysupporting

confidence: 55%

Influence of the Presence of Muscularis Propria on Recurrence and the Quality of Transurethral Resection in Low-Grade, Stage pTa Bladder Tumors

Türk¹,

Ün²,

Tarhan³

et al. 2016

jus

View full text Add to dashboard Cite

ÖZ AmaçYeni kasa invaze olmayan mesane tümörlerinin standart tedavisi mesanenin transüretral rezeksiyonu (TURM) ve intravezikal kemoterapidir. Yetersiz tümör rezeksiyonu, erken nüks ve düşük evreleme gibi hastalığın seyrini değiştirecek durumları ortaya çıkarmaktadır. Bu nedenle kasa invaze olmayan mesane tümörlerinin tedavisinde kaliteli TURM önemli bir faktördür. gereç ve yöntemPrimer mesane tümörü nedeniyle TURM olmuş 841 hasta çalışmaya alındı. Toplam 597 hasta bu kriterlerimize uymadığı için çalışmadan çıkarıldı. Grup 1'de patoloji spesmeninde müskülaris propria (MP) görülen hastalar bulunurken; grup 2, TURM örneğinde MP görülmeyen hastalardan oluşmuştur. Hastalar; cinsiyet, tümör sayısı, patoloji spesmenindeki tümör hacmi, MP durumu, nüks durumu, nüks zamanı ve progresyon açısından değerlendirildi. BulgularNüks eden 92 hastanın sadece 14'ünde (%15,2) MP bulunurken geriye kalan 78 (%84,8) hasta da MP görülmemiştir (p=0,004). Grup 1'de progrese olan hasta 4 (%14,2), grup 2'de 28 (%29) hasta olarak ortaya çıkmıştır (p=0,159). Tek değişkenli analizde, tümör multiplitesi (p=0,003) ve MP yokluğu (p=0,004) rekürrens üzerine etkili bulunmuştur. Çok değişkenli analizde yine bu iki parametre nüks üzerine etkili bulunmuştur (p=0,004). objectiveTransurethral resection (TUR) of the bladder and intravesical chemotherapy is the standard treatment option for non-muscle-invasive bladder tumors. Inadequate tumor resection results in early recurrence and staging inaccuracies, which all will change the course of the disease. High-quality TUR treatment is therefore an important factor in the treatment of non-muscle-invasive bladder tumors. In this study, we investigated the significance of detecting the presence of muscularis propria (MP) in pathology specimens of low-grade, stage pTa tumors in patients who were treated with TUR due to primary bladder tumors, with regard to recurrence, time to recurrence and progression. Materials and MethodsInitially, 841 patients who were treated with TUR due to primary bladder tumors were enrolled in the study. A total of 597 patients were excluded from the study because they failed to meet the study criteria. Group 1 consisted of patients with MP detected in the pathology specimens; whereas group 2 consisted of patients whose TUR specimens did not include MP. The patients were evaluated with regard to gender, tumor number, presence or absence of MP, and recurrence status. ResultsMP was observed in only 14 (15.2%) of 92 patients with recurrence, but not in the remaining 78 (84.8%) (p=0.004). Progression occurred in 4It was pointed out that muscularis propria presence in the pathology specimens of low-grade stage pTa tumours is an indicator of a high quality transurethral resection.

show abstract

Section: Mariappan Et Al (6) Have Demonstrated That (I) Multiplicitysupporting

confidence: 55%

Influence of the Presence of Muscularis Propria on Recurrence and the Quality of Transurethral Resection in Low-Grade, Stage pTa Bladder Tumors

Türk¹,

Ün²,

Tarhan³

et al. 2016

jus

View full text Add to dashboard Cite

show abstract

“…Several publications have focused on the high recurrence rate at the first follow-up cystoscopy after TUR due to an incomplete resection or residual tumor [37][38][39]. There is thus justification for giving an early intense schedule of instillations to eradicate residual tumor after TUR.…”

Section: Discussionmentioning

confidence: 99%

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

2008

Self Cite

View full text Add to dashboard Cite

Objectives-Intravesical chemotherapy has been studied in randomized clinical trials for >30 yr; however, the optimal schedule and duration of treatment are unknown. The objective is to determine the effect of schedule and duration of intravesical chemotherapy on recurrence in patients with stage Ta T1 bladder cancer.Methods-A systematic review was conducted of the published results of randomized clinical trials that compared intravesical instillations with respect to their number, frequency, timing, duration, dose, or dose intensity.

show abstract

“…Nestes casos, a detecção de invasão muscular aumenta em até 10% na segunda ressecção transuretral 22 (D). O tratamento e o prognóstico podem ser alterados pela presença ou ausência de tumor residual.…”

Section: (C)unclassified

Câncer de bexiga: diagnóstico

Patologia¹

2008

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

A Second-Look TUR in T1 Transitional Cell Carcinoma: Why?

Cited by 182 publications

References 46 publications

Influence of the Presence of Muscularis Propria on Recurrence and the Quality of Transurethral Resection in Low-Grade, Stage pTa Bladder Tumors

Influence of the Presence of Muscularis Propria on Recurrence and the Quality of Transurethral Resection in Low-Grade, Stage pTa Bladder Tumors

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

Câncer de bexiga: diagnóstico

Contact Info

Product

Resources

About